POSTER: CT-235 Lisocabtagene Maraleucel in Relapsed or Refractory (R/R) Follicular Lymphoma (FL; TRANSCEND FL): Impact of Prior Lines of Therapy (LOT), Bendamustine Exposure, and Disease Progression ≤24 Months of Initial Systemic Therapy (POD24)

Sairah Ahmed; Juan Luis Reguera Ortega; Franck Morschhauser; Guillaume Cartron; Aaron P. Rapoport; Koji Izutsu; Hervé Ghesquieres; M. Lia Palomba; Hideki Goto; John Kuruvilla; Jeremy S. Abramson; Peter Borchmann; Ulrich Jäger; Manali Kamdar; Merav Bar; Maria Strocchia; Martina Raggi; Rina Nishii; Alejandro Martín García-Sancho

doi:10.1016/S2152-2650(25)01392-8

$POSTER: CT-235 Lisocabtagene Maraleucel in Relapsed or Refractory (R/R) Follicular Lymphoma (FL; TRANSCEND FL): Impact of Prior Lines of Therapy (LOT), Bendamustine Exposure, and Disease Progression ≤24 Months of Initial Systemic Therapy (POD24)$

Article de revue

Avec comité de lecture

POSTER: CT-235 Lisocabtagene Maraleucel in Relapsed or Refractory (R/R) Follicular Lymphoma (FL; TRANSCEND FL): Impact of Prior Lines of Therapy (LOT), Bendamustine Exposure, and Disease Progression ≤24 Months of Initial Systemic Therapy (POD24)

Sairah Ahmed, Juan Luis Reguera Ortega, Franck Morschhauser, Guillaume Cartron, Aaron P. Rapoport, Koji Izutsu, Hervé Ghesquieres, M. Lia Palomba, Hideki Goto, John Kuruvilla, …

Clinical lymphoma, myeloma and leukemia, Vol.25, pp.S317-S317

09/2025

DOI: https://doi.org/10.1016/S2152-2650(25)01392-8

Indicateurs

1 Consultations de la notice

Détails

Titre: POSTER: CT-235 Lisocabtagene Maraleucel in Relapsed or Refractory (R/R) Follicular Lymphoma (FL; TRANSCEND FL): Impact of Prior Lines of Therapy (LOT), Bendamustine Exposure, and Disease Progression ≤24 Months of Initial Systemic Therapy (POD24)
Créateurs - sans rôle: Sairah Ahmed - MD Anderson Cancer Center, Houston, TX, USA
Juan Luis Reguera Ortega - Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Seville, Spain
Franck Morschhauser - Groupe de Recherche sur les formes Injectables et les Technologies Associées
Guillaume Cartron - Montpellier University Hospital Center, UMR CNRS 5535, Montpellier, France
Aaron P. Rapoport - University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA
Koji Izutsu - National Cancer Center Hospital, Tokyo, Japan
Hervé Ghesquieres - Hôpital Lyon Sud
M. Lia Palomba - Memorial Sloan Kettering Cancer Center
Hideki Goto - Hokkaido University Hospital
John Kuruvilla - Princess Margaret Cancer Centre, Toronto, ON, Canada
Jeremy S. Abramson - Harvard Medical School
Peter Borchmann - Universität zu Köln, Köln, Germany
Ulrich Jäger - Medical University of Vienna
Manali Kamdar - University of Colorado Cancer Center
Merav Bar - Bristol Myers Squibb, Seattle, WA, USA
Maria Strocchia - Bristol Myers Squibb, Boudry, Switzerland
Martina Raggi - Bristol Myers Squibb, Boudry, Switzerland
Rina Nishii - Bristol Myers Squibb, Princeton, NJ, USA
Alejandro Martín García-Sancho - Universidad de Salamanca
Détails de publication: Clinical lymphoma, myeloma and leukemia, Vol.25, pp.S317-S317
Éditeur: Elsevier Inc
Identifiants: 99139652409311
Unité académique: Institut de Génétique Moléculaire de Montpellier - IGMM
Langue: English
Type de ressource: Journal article